Gestational Diabetes Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The gestational diabetes market  reached a value of USD 10.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 16.7 Billion by 2036, exhibiting a growth rate (CAGR) of 4.47% during 2026-2036.

The gestational diabetes market has been comprehensively analyzed in IMARC's new report titled "Gestational Diabetes Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Gestational diabetes refers to a type of diabetes that can occur in pregnant women. It develops when the body is unable to produce enough insulin to control the increased demand for glucose over that period. This results in high levels of glucose in the blood, which can lead to various complications for both the mother and the baby. Moreover, a pregnant woman with this ailment is at a higher risk of developing Type 2 diabetes later in life. Some of the common symptoms of gestational diabetes include frequent urination, increased thirst, blurred eyesight, genital itching, excessive tiredness, etc. The diagnosis of this ailment relies on a screening test during the second trimester or between 24 and 28 weeks of pregnancy. The healthcare provider may perform an initial glucose challenge test, followed by glucose tolerance testing to measure the blood sugar level and confirm a diagnosis among patients.

To get more information on this market, Request Sample

The increasing cases of hormonal changes during pregnancy that make the body less capable of processing blood sugar or utilizing insulin are primarily driving the gestational diabetes market. In addition to this, the rising incidences of multiple associated risk factors, such as being overweight, having a sedentary lifestyle, family history of diabetes, heart disease, etc., are also bolstering the market growth. Furthermore, the inflating utilization of effective anti-diabetic drugs, involving glibenclamide and metformin, to lower glucose concentrations in the blood and treat the underlying symptoms in patients, is acting as another significant growth-inducing factor. Apart from this, the escalating application of non-pharmacological interventions, like lifestyle modifications, which include eating a healthy and balanced diet, exercising regularly, maintaining optimum body weight, etc., is further creating a positive outlook for the market. Additionally, the growing popularity of insulin pens over conventional syringe therapies to treat this condition since they are more convenient to use, provide greater dose accuracy, stabilize blood sugar, and enhance patient outcomes is expected to drive the gestational diabetes market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the gestational diabetes market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for gestational diabetes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gestational diabetes market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the gestational diabetes market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the gestational diabetes market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current gestational diabetes marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the gestational diabetes market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the gestational diabetes market across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the gestational diabetes market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2020-2036​) of gestational diabetes across the seven major markets?
• What is the number of prevalent cases (​2020-2036​) of gestational diabetes by age across the seven major markets?
• What is the number of prevalent cases (​2020-2036​) of gestational diabetes by gender across the seven major markets?
• How many patients are diagnosed (​2020-2036​) with gestational diabetes across the seven major markets?
• What is the size of the gestational diabetes patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend of gestational diabetes?
• What will be the growth rate of patients across the seven major markets?
   

Gestational Diabetes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for gestational diabetes drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gestational diabetes market?
• What are the key regulatory events related to the gestational diabetes market?
• What is the structure of clinical trial landscape by status related to the gestational diabetes market?
• What is the structure of clinical trial landscape by phase related to the gestational diabetes market?
• What is the structure of clinical trial landscape by route of administration related to the gestational diabetes market?